Sugi Predict

Sugi Predict / Targets / DCLK1

DCLK1

Serine/threonine-protein kinase DCLK1 · O15075 · DCLK1 on Sugi Atlas →

40,506 patent compounds predicted against DCLK1, 32,556 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL144378 SCHEMBL144378 0.66 3/20
SCHEMBL142020 SCHEMBL142020 0.65 3/20
SCHEMBL144118 SCHEMBL144118 0.61 3/20
SCHEMBL143818 SCHEMBL143818 0.61 3/20
SCHEMBL143827 SCHEMBL143827 0.59 3/20
SCHEMBL144183 SCHEMBL144183 0.58 3/20
SCHEMBL140610 SCHEMBL140610 0.56 3/20
SCHEMBL143148 SCHEMBL143148 0.56 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
SCHEMBL141930 SCHEMBL141930 0.90 2/20
SCHEMBL142206 SCHEMBL142206 0.85 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20
SCHEMBL143584 SCHEMBL143584 0.78 2/20
SCHEMBL143543 SCHEMBL143543 0.77 2/20
SCHEMBL144192 SCHEMBL144192 0.75 2/20
SCHEMBL143185 SCHEMBL143185 0.75 2/20

Clinical trials — most relevant to DCLK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma PHASE2/PHASE3UNKNOWN
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer PHASE2/PHASE3UNKNOWN
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer PHASE2UNKNOWN
DC Vaccine Combined With CIK Cells in Patients With SCLC PHASE1/PHASE2UNKNOWN
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC PHASE1/PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma PHASE1COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors EARLY_PHASE1UNKNOWN
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma nanCOMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) nanUNKNOWN
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy nanCOMPLETED
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer nanACTIVE_NOT_RECRUITING
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor nanUNKNOWN
Safety and Efficacy of Immune Therapy for Condyloma nanUNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DCLK1 binder may also engage these)

ProteinNameSimilarity
Q9JLM8 — 1.000 Q9JLM8 →
Q6PGN3 — 1.000 Q6PGN3 →
DCLK2 Serine/threonine-protein kinase DCLK2 1.000 landscape →
Q5MPA9 — 1.000 Q5MPA9 →
B4NSS9 — 1.000 B4NSS9 →
D2I3C6 — 0.999 D2I3C6 →
B5DK35 — 0.998 B5DK35 →
Q7PLI7 — 0.998 Q7PLI7 →
B4IMC3 — 0.997 B4IMC3 →
O08875 — 0.997 O08875 →
B4GXC2 — 0.996 B4GXC2 →
B4IT27 — 0.996 B4IT27 →
Q8BRK8 — 0.996 Q8BRK8 →
G5EFD2 — 0.995 G5EFD2 →
Q8AXB4 — 0.995 Q8AXB4 →
Q19469 — 0.995 Q19469 →
P42159 — 0.995 P42159 →
PAK3 Serine/threonine-protein kinase PAK 3 0.995 landscape →
Q9H1H9 — 0.994 Q9H1H9 →
U4PR86 — 0.994 U4PR86 →
Q95QC4 — 0.994 Q95QC4 →
B3NKK1 — 0.994 B3NKK1 →
Q19546 — 0.994 Q19546 →
O97143 — 0.994 O97143 →
O88809 — 0.994 O88809 →
O43150 — 0.994 O43150 →
Q2LYK3 — 0.993 Q2LYK3 →
Q7YQL4 — 0.993 Q7YQL4 →
DCX Neuronal migration protein doublecortin 0.993 landscape →
P25799 — 0.993 P25799 →